$ULBI
ULTRALIFE CORP Stock $ulbi

$ulbi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923012590 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$42.69M	$31.92M
YoY Change	32.89%	5.08%
Cost Of Revenue	$32.10M	$24.48M
YoY Change	31.14%	4.55%
Gross Profit	$10.59M	$7.436M
YoY Change	38.48%	6.87%
Gross Profit Margin	24.8%	23.3%
Selling, General & Admin	$4.942M	$5.378M
YoY Change	-4.61%	-0.33%
% of Gross Profit	46.68%	72.32%
Research & Development	$1.754M	$2.032M
YoY Change	4.9%	9.42%
% of Gross Profit	16.57%	27.33%
Depreciation & Amortization	$987.0K	$762.0K
YoY Change	20.51%	-6.62%
% of Gross Profit	9.32%	10.25%
Operating Expenses	$6.923M	$7.410M
YoY Change	1.02%	2.16%
Operating Profit	$3.665M	$26.00K
YoY Change	362.17%	-108.81%
Interest Expense	-$440.0K	-$424.0K
YoY Change	148.59%	216.42%
% of Operating Profit	-12.01%	-1630.77%
Other Income/Expense, Net	$1.498M	-$494.0K
YoY Change	-1402.61%	322.22%
Pretax Income	$4.723M	-$468.0K
YoY Change	596.61%	13.59%
Income Tax	$1.375M	-$133.0K
% Of Pretax Income	29.11%
Net Earnings	$3.340M	-$346.0K
YoY Change	552.34%	105.95%
Net Earnings / Revenue	7.82%	-1.08%
Basic Earnings Per Share	$0.21	-$0.02
Diluted Earnings Per Share	$0.21	-$0.02
COMMON SHARES
Basic Shares Outstanding	16.14M	16.14M
Diluted Shares Outstanding	16.14M	16.14M

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.202M	$5.605M
YoY Change	60.38%	-7.36%
Cash & Equivalents	$8.202M	$5.524M
Short-Term Investments
Other Short-Term Assets	$4.931M	$3.973M
YoY Change	-4.46%	4.47%
Inventory	$46.06M	$47.31M
Prepaid Expenses
Receivables	$28.63M	$24.46M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$87.83M	$81.35M
YoY Change	22.28%	17.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.31M	$21.41M
YoY Change	4.35%	-4.15%
Goodwill	$37.50M	$37.52M
YoY Change	0.0%	-1.08%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.20M	$2.160M
YoY Change	395.53%	-20.03%
Total Long-Term Assets	$87.57M	$89.80M
YoY Change	-3.13%	-2.65%
TOTAL ASSETS
Total Short-Term Assets	$87.83M	$81.35M
Total Long-Term Assets	$87.57M	$89.80M
Total Assets	$175.4M	$171.2M
YoY Change	8.12%	6.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.54M	$18.99M
YoY Change	37.94%	69.01%
Accrued Expenses	$8.662M	$8.211M
YoY Change	28.61%	21.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$29.20M	$29.20M
YoY Change	31.69%	45.89%
LONG-TERM LIABILITIES
Long-Term Debt	$22.64M	$21.13M
YoY Change	15.72%	5.73%
Other Long-Term Liabilities	$1.996M	$1.969M
YoY Change	50.3%	25.1%
Total Long-Term Liabilities	$24.64M	$23.10M
YoY Change	17.92%	7.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.20M	$29.20M
Total Long-Term Liabilities	$24.64M	$23.10M
Total Liabilities	$55.86M	$54.75M
YoY Change	23.71%	25.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.96M	-$48.30M
YoY Change	-5.33%	0.62%
Common Stock	$2.059M	$2.057M
YoY Change	0.1%	0.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$119.5M	$116.3M
YoY Change
Total Liabilities & Shareholders Equity	$175.4M	$171.2M
YoY Change	8.12%	6.05%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	$3.340M	-$346.0K
YoY Change	552.34%	105.95%
Depreciation, Depletion And Amortization	$987.0K	$762.0K
YoY Change	20.51%	-6.62%
Cash From Operating Activities	$1.751M	-$1.365M
YoY Change	-1083.71%	-57.64%
INVESTING ACTIVITIES
Capital Expenditures	$516.0K	$497.0K
YoY Change	-341.12%	33.96%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$516.0K	-$497.0K
YoY Change	141.12%	33.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.562M	$1.800M
YoY Change	-464.1%	47.18%
NET CHANGE
Cash From Operating Activities	1.751M	-$1.365M
Cash From Investing Activities	-516.0K	-$497.0K
Cash From Financing Activities	1.562M	$1.800M
Net Change In Cash	2.797M	-$108.0K
YoY Change	-440.68%	-95.43%
FREE CASH FLOW
Cash From Operating Activities	$1.751M	-$1.365M
Capital Expenditures	$516.0K	$497.0K
Free Cash Flow	$1.235M	-$1.862M
YoY Change	3330.56%	-48.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-497000	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000875657
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	24480000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	23415000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	7436000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	6958000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2032000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1857000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5378000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5396000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7410000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7253000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	26000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-295000	usd
CY2023Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	424000	usd
CY2022Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	134000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-494000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-468000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-412000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-133000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-251000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-335000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-161000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-346000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-168000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	197000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-236000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	149000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-404000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16135000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16104000
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16135000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16104000
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q1	us-gaap	Depreciation Depreciation	762000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	816000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	209000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	328000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	139000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	189000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	390000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	402000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3365000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2724000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6026000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3274000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-639000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-977000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	256000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1022000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1365000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3222000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	497000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	371000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	113000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-371000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2300000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1450000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	500000	usd
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	333000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	113000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	-0	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1800000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1223000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-46000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-108000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2363000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5713000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8413000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5605000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6050000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117743000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-161000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	106000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	181000	usd
CY2022Q1	ulbi	Adjustments To Additional Paid In Capital Sharebased Compensation Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRestrictedStockRequisiteServicePeriodRecognition	8000	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-236000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117641000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116403000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-335000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5524000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5634000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	81000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	79000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5605000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5713000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	32960000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	29200000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4594000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2757000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9757000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9235000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	47311000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	41192000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	93164000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	92660000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	71752000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	70944000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21412000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21716000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	762000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	816000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	37428000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	90000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	37518000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28140000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12393000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15747000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28060000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12139000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15921000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	209000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	328000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	189000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1425693
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.72
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12500
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.07
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	17582
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.57
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1420611
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.69
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M29D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1295019
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.75
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	911553
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.09
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y3M14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.284	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.609	pure
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	241000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	233000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	28000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	24000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	269000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	257000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	226000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	227000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	697000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	519000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	215000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	217000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	217000	usd
CY2023Q1	ulbi	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	426000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2291000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	255000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	323000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	133000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	84000	usd
CY2022Q1	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	18000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	21000	usd
CY2022Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	31000	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	386000	usd
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	120000	usd
CY2023Q1	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	985000	usd
CY2022Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	682000	usd
CY2023Q1	us-gaap	Revenues Revenues	31916000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	26000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-494000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-133000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-346000	usd
CY2022Q1	us-gaap	Revenues Revenues	30373000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-295000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-251000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-168000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31916000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	30373000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31916000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	30373000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001437749-23-012590-index-headers.html	Edgar Link	pending
0001437749-23-012590-index.html	Edgar Link	pending
0001437749-23-012590.txt	Edgar Link	pending
0001437749-23-012590-xbrl.zip	Edgar Link	pending
ex_505235.htm	Edgar Link	pending
ex_505236.htm	Edgar Link	pending
ex_505237.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ulbi-20230331.xsd	Edgar Link	pending
ulbi20230331_10q.htm	Edgar Link	pending
ulbi-20230331_cal.xml	Edgar Link	unprocessable
ulbi-20230331_def.xml	Edgar Link	unprocessable
ulbi-20230331_lab.xml	Edgar Link	unprocessable
ulbi-20230331_pre.xml	Edgar Link	unprocessable
ulbi20230331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ULBI
ULTRALIFE CORP Stock $ulbi

2023 Q2 Form 10-Q Financial Statement

#000143774923012590 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ULBI ULTRALIFE CORP Stock $ulbi

2023 Q2 Form 10-Q Financial Statement

#000143774923012590 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ULBI
ULTRALIFE CORP Stock $ulbi